A Swiss study measuring cannabis brain damage biomarkers study results in 331 regular users found no evidence of nerve damage and unexpectedly lower levels of brain injury markers. These objective biomarker findings challenge assumptions about cannabis neurotoxicity but require further validation through longitudinal research.
Randomised Controlled Trial Evidence on Medicinal Cannabis for Treatment of Mental Health and Substance Use Disorders: A Scoping Review.
A comprehensive scoping review of randomized controlled trials reveals limited high-quality medicinal cannabis mental health evidence for treating psychiatric and substance use disorders. The systematic review highlights significant gaps in rigorous clinical trial data despite growing patient interest in cannabis for mental health applications.
Health-related quality of life in patients receiving medicinal cannabis: systematic review and meta-analysis of primary research findings 2015-2025.
A comprehensive systematic review and meta-analysis examining medicinal cannabis quality of life outcomes found consistent improvements across chronic conditions. The research analyzed validated HRQL measures from 2015-2025, showing benefits in short, medium, and long-term follow-up periods across diverse patient populations.
Patient perspectives on non‑traumatic painful upper‑extremity conditions, co-occurring risky substance use, and an integrated web-based mind-body intervention addressing both conditions.
Recent qualitative research examining upper extremity pain and substance use management reveals patients commonly use alcohol, cannabis, and tobacco for symptom relief but lack awareness of pain-substance interactions. The study provides insights for improving clinical communication and intervention design in this complex patient population.
Cognitive performance and subjective effects the morning after last use of smoked cannabis by adults who use cannabis frequently: An observational study.
A controlled observational study found no cognitive impairment in regular cannabis users 12-15 hours after smoking, with important implications for understanding cannabis cognitive effects next day. This research provides evidence that cognitive function returns to baseline within this timeframe for regular users, though individual variation remains important.
Therapeutically Motivated Cannabis Use for Anxiety: Daily and Longitudinal Reductions Vary Between Flower and Edible Products.
A 30-day study of therapeutic cannabis users found that flower products provided superior anxiety relief compared to edibles. This cannabis flower vs edibles anxiety relief study offers preliminary guidance for product selection in anxiety management, though individual responses vary significantly between patients.
Randomized and Blind Evaluation of the Efficacy of a Full-Spectrum Oral
A randomized controlled trial found that full-spectrum cannabis extract provided significant pain relief for dogs with chronic osteoarthritis compared to placebo. This cannabis osteoarthritis clinical trial adds controlled evidence supporting cannabinoid analgesic effects in degenerative joint disease. The findings warrant further investigation in human osteoarthritis populations.
Reducing severe breathlessness with dronabinol in the group of patients with severe and very severe chronic obstructive pulmonary disease (BONG): a randomised, double-blinded, placebo-controlled, crossover study in an outpatient clinic in Denmark
A new randomized crossover trial will investigate whether dronabinol COPD breathlessness treatment can help patients with severe symptoms. This protocol review examines the study design and clinical context for cannabis medicine in respiratory care.
Analgesic Effect of Cannabinoids for Fibromyalgia: A Systematic Review and Meta-Analysis.
A systematic review and meta-analysis found that cannabinoids for fibromyalgia pain relief show measurable analgesic benefits across randomized trials. This evidence supports considering cannabinoids as a potential treatment option for fibromyalgia patients experiencing inadequate pain control with conventional therapies.
Cannabis-based medicines for chronic neuropathic pain in adults.
The 2025 Cochrane review on cannabis neuropathic pain provides the most rigorous analysis of cannabinoid effectiveness for chronic nerve pain. This systematic review update incorporates recent trial data to inform evidence-based clinical decision-making for neuropathic pain treatment options.